7,560.00

-14.50

-0.19%

51,647.00

-486.00

-0.93%

28,161.75

+34.25

+0.12%

Russell 2000 Futures

2,810.70

-7.10

-0.25%

4.8940

-0.0350

-0.71%

21.55

+0.40

+1.89%

3,912.80

-56.80

-1.43%

77,059.46

-614.78

-0.79%

Crude Oil Dec 26

98.64

+2.18

+2.26%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqGS - Delayed Quote USD

SpyGlass Pharma, Inc. (SGP)

33.64 +1.40 (+4.34%)

At close: November 2 at 4:00:01 PM EST

Loading Chart for SGP

Chart Range Bar

Interval:

In partnership with ChartIQ

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space

SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

SpyGlass Pharma (SGP) Reports Positive 4 Year Glaucoma Trial Results

SpyGlass Pharma (SGP) Reports Positive 4 Year Glaucoma Trial Results

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Mobilize your Website

View Site in Mobile | Classic

Share by: